Stockreport

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Evogene Ltd. - Ordinary Shares  (EVGN) 
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am Check Earnings Report
US:NYSE Investor Relations: evogene.com/investor-relations
PDF Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and [Read more]